Truseltiq

Indicated For

cholangiocarcinoma

About This Medication

# Truseltiq (Infigratinib) Patient Guide: How to Get Truseltiq at Low or No Cost **Important Notice: Truseltiq (infigratinib) has been withdrawn from the US market by the FDA as of May 16, 2024, and is no longer available through any prescription assistance program.** This guide provides historical context on the former ForgingBridges support program and explains why assistance is unavailable today. Patients should consult their doctor for alternative treatments for cholangiocarcinoma.[1][6] ## About Truseltiq (Infigratinib) Truseltiq was an oral kinase inhibitor approved by the FDA on May 28, 2021, under accelerated approval for adults with previously treated, unresectable, locally advanced, or metastatic cholangiocarcinoma (bile duct cancer) harboring **FGFR2 fusions or other rearrangements**, confirmed by an FDA-approved test.[1][6] It targeted FGFR1-3 proteins to slow cancer growth in this rare subset of patients. The recommended dose was **125 mg orally once daily for 21 days, followed by 7 days off**, in 28-day cycles, taken on an empty stomach. Lower doses applied for renal or hepatic impairment (e.g., 100 mg or 75 mg).[1] In the pivotal phase 2 trial, it showed a 23% overall response rate (1 complete, 24 partial responses) with a median duration of 5 months among patients with metastatic disease post-chemotherapy.[1] **Key caveat:** Approval was contingent on confirmatory trials, which did not verify clinical benefit, leading to voluntary market withdrawal by manufacturer **BridgeBio Pharma / QED Therapeutics** in 2024.[6] No new patients can access it, and existing supplies are unavailable. ## Who Qualifies for Assistance? No specific patient assistance program (PAP) exists today due to the drug's withdrawal.[6] Historically, the **ForgingBridges** program by QED Therapeutics offered robust support for access and treatment journey aid, praised by experts for helping patients with FGFR2-altered cholangiocarcinoma.[1] It likely targeted uninsured or underinsured patients facing high costs, but details like income thresholds are unavailable post-withdrawal. **Income Eligibility Breakdown** | Household Size | Income Threshold | FPL % | Notes | |---------------|------------------|-------|-------| | Individual | Not available | N/A | Program discontinued; no PAP found[6] | | Couple | Not available | N/A | Historical ForgingBridges may have used standard pharma criteria (e.g., <400-500% FPL), but unconfirmed | | Family of 3 | Not available | N/A | Contact manufacturer for archives if needed | | Family of 4 | Not available | N/A | Withdrawal overrides all prior eligibility | Eligibility typically required US residency, valid prescription, and financial need, excluding government insurance in some cases.[3] ## Insurance Requirements Pre-withdrawal, Truseltiq was available via specialty pharmacies, with coverage varying by plan.[3] Co-pay cards reduced out-of-pocket costs for commercially insured patients; patient assistance applied if uninsured or denied coverage.[1][3] Medicare patients might have faced hurdles, as many PAPs exclude federal programs—consult your provider.[3] Post-withdrawal, insurance no longer covers it.[6] ## Step-by-Step Application Process **Current Status:** No applications accepted; drug unavailable.[6] **Historical ForgingBridges Process (for reference):** 1. **Confirm Eligibility:** Doctor verifies FGFR2 alteration via FDA-approved test and discusses with patient.[1] 2. **Contact Support:** Call ForgingBridges (details once at forgingbridges.com or manufacturer helpline; now defunct).[1] 3. **Gather Documents:** Prescription, proof of income, insurance denial (if applicable), ID.[3] 4. **Submit Application:** Via phone, online portal, or HCP portal—specialty pharmacy coordinated delivery.[1][3] 5. **Approval Wait:** Case managers reviewed; monthly check-ins for refills.[1] 6. **Receive Medication:** Shipped free to patient or doctor's office.[3] ## Timeline and Delivery Processing was not detailed but similar programs approve in weeks, with monthly shipments.[1][4] Delivery via mail or pharmacy pickup; take on schedule to avoid missing doses.[5] ## Alternatives if Denied or Unavailable - **Discuss with Oncologist:** Explore FGFR inhibitors like **pemigatinib (Pemazyre)** or **futibatinib (Lytgobi)** for FGFR2-altered cholangiocarcinoma, with their own PAPs.[1] - **General Resources:** NeedyMeds, PAN Foundation, or CancerCare for cholangiocarcinoma support. - **Clinical Trials:** Search ClinicalTrials.gov for FGFR-targeted therapies. - **Manufacturer Contact:** BridgeBio/QED for compassionate use (unlikely post-withdrawal). - **Biosimilars:** None available.[6] ## Disclaimer This guide is for informational purposes only and not medical advice. Truseltiq is **no longer available**; do not seek it.[6] Eligibility, processes, and availability change—verify with healthcare provider, manufacturer (BridgeBio Pharma / QED Therapeutics), or FDA. Costs, rules vary by state/insurance. Consult professionals for personalized guidance. Word count: 912.

Program information last verified: March 25, 2026